Apitope announces that the first in human clinical trial for the treatment of Graves’ disease has been published as a ‘Success Story’ by the European Commission

Apitope announces that the first in human clinical trial for the treatment of Graves’ disease has been published as a ‘Success Story’ by the European Commission

HASSELT, Belgium, and CHEPSTOW, UK, 13 September 19 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces that the first in human clinical trial for the treatment of Graves’ disease funded by the European Union (DAVIAD) has been published as a “Success Story” on the European Union website. The article entitled ‘ New treatment on the horizon for Graves’ disease’ can be viewed in the following link:

https://ec.europa.eu/research/infocentre/article_en.cfm?artid=50625

Apitope to present at ECTRIMS 2019 Stockholm, Sweden

Professor David Wraith Apitope’s founder and CSO and Dr Lotta Jansson, Chief Research Officer are scheduled to attend ECTRIMS 2019. The conference is being held in Stockholm Sweden between 11th-13th September ECTRIMS 2019 at the Stockholmsmässan.

Professor Wraith will present during Session 12 entitled ‘Immunopathogenesis and antigen specific therapies’ details of which are below:

13 September 2019
Presentation: A future for antigen specific immunotherapy for multiple sclerosis
Time: 08:50am
Presenter: David Wraith

Apitope to present at Immunity for Health 2019 – Hasselt, Belgium

Professor David Wraith Apitope’s co-founder and CSO will present as an invited speaker at Immunity for Health 2019. The conference theme is Therapeutic Vaccines & Immunotherapy and is being held University Hasselt, Belgium on 15th October 2019.

15 October 2019
Key Note Presentation: The Future of Immunotherapy: A 20-Year Perspective
Time: 15:50
Presenter: David Wraith

Apitope to present at American College of Toxicology and Council

Professor David Wraith Apitope’s co-founder and CSO will present as an invited speaker at the 40th Annual Meeting, 17-20 November, 2019, at the JW Marriott Desert Ridge in Phoenix, Arizona.
Professor Wraith will present during Session 10 entitled ‘Immune Tolerance: State-of-the-Science and Preclinical and Clinical Safety Challenges in Drug Development’:

19 November 2019
Presentation: State-of-Science of Immune Tolerance, and Trending Therapeutic Concepts for New and Differentiated Mechanisms of Action
Time: 09:00am
Presenter: David Wraith

Apitope Announces Publication of Data in International Peer-Reviewed Journal Thyroid on Graves’ disease Therapy

HASSELT, Belgium, and CHEPSTOW, UK, 20 June 19 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announces publication of its clinical Graves’ disease data in Thyroid, one of the leading peer-reviewed thyroid disease related medical journals.

The publication entitled: Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves’ Hyperthyroidism: A Phase I Study , reports the results from a first in human clinical study to assess the safety, tolerability and efficacy of Apitope’s antigen-specific immunotherapy, ATX-GD-59, in patients with Graves’ disease.

The open-label trial reported in the paper was conducted in patients with mild to moderate Graves’ disease. These preliminary data suggest that ATX-GD-59 is a safe and well-tolerated treatment. The improvement in free thyroid function in 70% of subjects receiving the medication suggests potential efficacy as a novel treatment for Graves’ hyperthyroidism.
Hayley French, CEO of Apitope, said: “We are delighted that these data have been published in Thyroid, a peer-reviewed journal for thyroid related diseases. For people suffering from Graves’, the project’s progress has finally created hope that the underlying disease can be treated and, for the first time in over 70 years, an innovative disease modifying treatment could be on the horizon”.

https://www.liebertpub.com/doi/full/10.1089/thy.2019.0036

Apitope presents at 2nd Antigen-Specific Immune Tolerance Summit Boston MA 2019

HASSELT, Belgium, and CHEPSTOW, UK, 29 March 2019 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, announces that Chief Research Officer Dr Lotta Jansson and Chief Scientific Officer Professor David Wraith attended and presented  at the  2nd Antigen-Specific Immune Tolerance Summit Boston MA 2019  conference held on 26 -28 March 2019.

27 March 2019

Presentation: Antigen-Specific Immunotherapy for Treatment of Autoimmune

Presenter: Professor David Wraith

The presentation was part of the session ‘Addressing Knowledge Gap in Immune Tolerance Induction by Connecting the Dots Between Transplantation, Allergies & Autoimmune Diseases’

27 March 2019

Panel Discussion: How to Identify & Prioritize the Route to Success for Antigen-Specific Immune Tolerance Induction Strategies?

Dr Lotta Jansson joined a panel discussion along with Charlotte Fribert, Toleranzi AB (Moderator), Matthias von Herrath, Novo Nordisk, David Alleva, Akston Biosciences and Joshua Sestak, Orion BioScience

The panel was part of the session on ‘Advancing Pre-Clinical Development of Novel Antigen-Specific Immune Tolerance Therapies’

28 March 2019

Panel Discussion: Evaluation of Combination Therapies to Address Unmet Clinical Needs

Dr Lotta Jansson joined a panel discussion along with David Alleva, Akston Biosciences, Amy Rosenberg, CDER/FDA and Pieter Rottiers, ActoBio Therapeutics. The panel was part of the session ‘The Future Landscape of Antigen-Specific Immune Tolerance Therapies: The Promise of Combination Strategies’ 

A poster was also presented at the meeting  entitled ‘Treating autoimmune diseases with tolerogenic peptides – apitopes®

Apitope to present at 1st Antigen-Specific Immune Tolerance Europe Conference

HASSELT, Belgium, and CHEPSTOW, UK, 10 December 2018 – Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, announces that Non-Executive Director Dr Keith Martin and Chief Scientific Officer Prof David Wraith are scheduled to attend and present at the Antigen-Specific Immune Tolerance Europe 2018 conference being held in London on 10th-12th December. The conference will be held at Park Plaza Victoria.

Dr Martin and Dr Wraith’s presentation details are below.

11th December 2018

Presentation: Antigen-Specific Immunotherapy of Autoimmune Diseases
Time: 09:00am
Presenter: David Wraith

The presentation is part of the session on ‘Harnessing Tregs to Induce Antigen-Specific Immune Tolerance’.

12th December 2018

Panel Discussion: Improving Pre-Clinical Predictability of Antigen-Specific Immune Tolerance Therapies
Time: 10:30am

Dr Keith Martin to join panel discussion along with Timm Jessen, Topas Therapeutics and Pieter Rottiers, ActoBio Therapeutics. The panel is part of the session on ‘Overcoming Translational Challenges of Antigen-Specific Immune Tolerance Therapies into the Clinic’.

Presentation: Antigen Specific Immunotherapy with Apitopes® from Concept to Clinic”
Time: 11:30am
Presenter: Dr Keith Martin

The presentation is part of the session on ‘Optimizing Clinical Development & Paving the Future of Antigen-Specific Immune Tolerance Therapies’.

Antigen-Specific Immune Tolerance Europe 2018 is the first European centric, dedicated platform that brings key decision makers together to successfully translate ground breaking science into a novel class of therapies to treat autoimmunity. The Conference will be will be dedicated to determining novel antigen identification, validation of preclinical models and ultimately the effective clinical translation of this research clinical setting.